<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111878</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP119</org_study_id>
    <nct_id>NCT00111878</nct_id>
  </id_info>
  <brief_title>Study to Evaluate MEDI-534 in Healthy Adults</brief_title>
  <official_title>Dose-Escalating Study to Evaluate MEDI-534 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to describe the safety and tolerability of a single
      dose of MEDI-534 when administered to healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>December 2005</completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>120</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <condition>Parainfluenza Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-534</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ages 18 through 40 years (not yet reached their 41st birthday) on the
             day of randomization

          -  Healthy by medical history and physical examination

          -  Available by telephone

          -  Signed written informed consent and Health Insurance Portability and Accountability
             Act (HIPAA) authorization obtained from the volunteer

          -  Sexually active females, unless surgically sterile or at least 1 year post-menopausal,
             must have used an effective method of avoiding pregnancy (including oral, implanted,
             or transdermal contraceptives, intrauterine device (IUD), female condom, diaphragm
             with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or
             sterile sexual partner) for at least 30 days prior to dosing of study vaccine, and
             must agree to continue using such precautions for at least 30 days after dosing; the
             volunteer must also have a negative serum pregnancy test within 7 days prior to dosing
             of study vaccine and a negative urine pregnancy test on the day of study vaccine
             dosing prior to administration

          -  Sexually active males, unless surgically sterile, must use an effective method of
             birth control (condom or abstinence) and must agree to continue using such precautions
             for at least 30 days after dosing

          -  Ability to understand and comply with the requirements of the protocol as judged by
             the investigator

          -  Ability to complete the follow-up period of 6 months following dosing as required by
             the protocol

        Exclusion Criteria:

          -  Acute illness on the day of randomization

          -  Fever (greater than or equal to 99.5°F oral or greater than or equal to 100.1°F
             tympanic) and/or respiratory illness (e.g., cough or sore throat) within 7 days prior
             to randomization

          -  Any drug therapy (chronic or other) within 7 days prior to randomization (except for
             certain medications such as contraceptives, topical [i.e., dermatologic]
             corticosteroids, or infrequent use of over-the-counter pain relievers, following
             approval from the sponsor) or expected receipt through 28 days after study vaccine
             dosing

          -  Receipt of immunoglobulin or blood products within 90 days prior to screening or
             expected receipt through 28 days after study vaccine dosing

          -  Receipt of any investigational drug within 60 days prior to randomization or expected
             receipt during the study period (i.e., through 180 days after study vaccine dosing)

          -  Receipt of an approved vaccine within 30 days prior to randomization or expected
             receipt through 28 days after study vaccine dosing

          -  History of immunodeficiency or receipt of immunosuppressive agents, or expected
             receipt of an immunosuppressive agent through 28 days after study vaccine dosing

          -  Close contact at home or in the workplace with children under 2 years of age

          -  Household contact who is immunocompromised; volunteer should also avoid close contact
             with immunocompromised individuals for at least 21 days after vaccination

          -  History of hypersensitivity to kanamycin or other aminoglycoside antibiotics
             (gentamicin, tobramycin, etc.)

          -  Previous medical history, or evidence, of an intercurrent or chronic illness that, in
             the opinion of the investigator, may compromise the safety of the volunteer

          -  Any evidence of end organ dysfunction

          -  Current, or history of, clinically significant abnormality on electrocardiogram (ECG)
             (screening ECG must be within 30 days prior to randomization)

          -  Evidence of active infection with HIV or hepatitis A, B, or C virus, or serologic
             evidence of past infection with hepatitis B or C virus

          -  At screening (must be within 7 days prior to randomization), any of the following
             laboratory tests outside of the laboratory normal range: CBC: hemoglobin (Hgb), WBC
             count, platelet count; AST, ALT, BUN, creatinine; or other abnormal laboratory value
             in the screening panel that, in the opinion of the principal investigator, may
             potentially confound analysis of study results

          -  Nursing mother

          -  History of alcohol or drug abuse in the past 2 years

          -  History of medical diagnosis of asthma, reactive airway disease, or chronic
             obstructive pulmonary disease (COPD)

          -  History of any smoking in the past 5 years

          -  Previous vaccination against Respiratory Syncytial Virus (RSV) or Parainfluenza Virus
             Type 3 (PIV3) in a clinical trial

          -  Employees of the research center, any individuals involved with the conduct of the
             study, or family members of such individuals

          -  Any condition that, in the opinion of the investigator, might interfere with study
             vaccine evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margarita Gomez, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2005</study_first_submitted>
  <study_first_submitted_qc>May 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2005</study_first_posted>
  <last_update_submitted>July 2, 2007</last_update_submitted>
  <last_update_submitted_qc>July 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2007</last_update_posted>
  <keyword>Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Paramyxoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

